Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02390414 · ClinicalTrials.gov registry record
The Myelodysplasia Transplantation-Associated Outcomes (MDS-TAO) Study
A clinical trial, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- 290
- Enrollment target
NCT02390414 is a clinical trial that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 290 participants.
The verdict
NCT02390414 has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- 290 participants
- Enrollment target
Study Summary
The purpose of this observational study is to compare overall survival in older adults with myelodysplastic syndromes (MDS) who receive reduced intensity conditioning hematopoietic stem cell transplant (RIC HSCT) versus those who do not receive HSCT.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 290 participants |
| Start Date | 2011-05 |
| Est. Completion | 2020-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02390414
The ClinicalTrials.gov registry entry for NCT02390414 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 290 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02390414 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02390414 about?
NCT02390414 is a clinical study titled "The Myelodysplasia Transplantation-Associated Outcomes (MDS-TAO) Study". The purpose of this observational study is to compare overall survival in older adults with myelodysplastic syndromes (MDS) who receive reduced intensity conditioning hematopoietic stem cell transplant (RIC HSCT) versus those who do not receive HSCT.
What is the current status of trial NCT02390414?
This trial is currently completed. The enrollment target is 290 participants. The study started on 2011-05. Estimated completion is 2020-09.
Who is sponsoring clinical trial NCT02390414?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.